A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01181167 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 610
Last updated 2019-03-05
Summary
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
Conditions
- Prevention
- Venous Thromboembolism
Interventions
- DRUG
-
edoxaban
- DRUG
-
enoxaparin sodium
Sponsors & Collaborators
-
Daiichi Sankyo Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Takeshi Fuji · Osaka Koseinenkin Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 84 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-05-31
- Primary Completion
- 2010-01-31
- Completion
- 2010-03-31
Countries
- Japan
Study Locations
More Related Trials
-
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
NCT00168818 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
NCT00107900 ·Status: COMPLETED ·Phase: PHASE2
-
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
NCT00657150 ·Status: COMPLETED ·Phase: PHASE3
-
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
NCT00152971 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
NCT00986154 ·Status: COMPLETED ·Phase: PHASE3
-
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
NCT00846807 ·Status: COMPLETED
-
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
NCT00353678 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
NCT00913120 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00371683 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03891524 ·Status: COMPLETED ·Phase: PHASE2
-
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
NCT00423319 ·Status: COMPLETED ·Phase: PHASE3
-
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
NCT00074828 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
NCT00902928 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
NCT01857583 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Ranging Study in Elective Total Hip Replacement Surgery
NCT00338897 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
NCT00408239 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
NCT00306254 ·Status: COMPLETED ·Phase: PHASE2
-
Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty
NCT02379663 ·Status: COMPLETED ·Phase: PHASE4
-
Edoxaban Management in Diagnostic and Therapeutic Procedures
NCT02950168 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03251482 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
NCT00937911 ·Status: COMPLETED ·Phase: PHASE3
-
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00452530 ·Status: COMPLETED ·Phase: PHASE3
-
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
NCT00168805 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
NCT00917254 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
NCT00721760 ·Status: COMPLETED ·Phase: PHASE3